Cumberland Partners Ltd Has $28.74 Million Stock Position in Astrazeneca Plc $AZN

Cumberland Partners Ltd boosted its position in shares of Astrazeneca Plc (NYSE:AZN) by 16.2% in the 1st quarter, HoldingsChannel reports. The firm owned 145,746 shares of the company’s stock after buying an additional 20,334 shares during the period. Astrazeneca accounts for about 2.2% of Cumberland Partners Ltd’s investment portfolio, making the stock its 18th largest holding. Cumberland Partners Ltd’s holdings in Astrazeneca were worth $28,744,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after acquiring an additional 11,690 shares during the last quarter. Amundi boosted its holdings in shares of Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after acquiring an additional 3,618 shares in the last quarter. Jump Financial LLC grew its position in Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after acquiring an additional 559 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Price Performance

AZN opened at $168.68 on Friday. The company has a fifty day moving average price of $180.55 and a two-hundred day moving average price of $187.97. The firm has a market capitalization of $261.61 billion, a PE ratio of 25.33, a P/E/G ratio of 1.37 and a beta of 0.24. Astrazeneca Plc has a 52 week low of $142.98 and a 52 week high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. As a group, analysts anticipate that Astrazeneca Plc will post 10.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Astrazeneca has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.